Compass Therapeutics, Inc.
Compass Therapeutics, Inc. scores highest on Anchor (54) and lowest on Nitro (13). Its PosiPenta is 39.34 out of 100, weaker than most similar companies.
On the Penta Grid this week, Compass Therapeutics, Inc. is Grid #563 of 837 in the Healthcare sector in United States, and Grid #2,952 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Compass Therapeutics, Inc. | 39.34 | 40 | 39 | 13 | 51 | 54 |
| Protara Therapeutics, Inc. | 36.30 | 41 | 29 | 13 | 61 | 38 |
| Journey Medical Corporation | 45.77 | 15 | 69 | 45 | 43 | 56 |
| Codexis, Inc. | 32.46 | 16 | 46 | 40 | 24 | 37 |
| KORU Medical Systems, Inc. | 48.05 | 9 | 82 | 34 | 57 | 58 |
| WW International, Inc. | 53.66 | 94 | 53 | 37 | 36 | 48 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -2.21 |
| P/B ratio | 0.93 |
EEarnings
| Trailing EPS | ₹-36.94 |
| Forward EPS | ₹-50.96 |
NNitro
| Price | 81.45 |
| 52-week high | 651.64 |
| 52-week low | 77.86 |
| Fall from 52-week high | 87.5% |
TTorque
| Return on equity (ROE) | -56.66% |
| Debt-to-equity | 0.06 |
AAnchor
| Beta (price swings) | 0.91 |
| Market cap | ₹1,466 Cr |
| Insider holding | 12.47% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Compass Therapeutics, Inc.'s PosiPenta score?
Compass Therapeutics, Inc.'s PosiPenta is 39.34 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Compass Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Compass Therapeutics, Inc. is Grid #563 of 837 in the Healthcare sector in United States, and Grid #2,952 of 4,000 in United States.
Which PosiPenta pillar is strongest for Compass Therapeutics, Inc.?
Anchor (stability and dividends), with a score of 54 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Compass Therapeutics, Inc.?
Nitro (momentum), with a score of 13 out of 100: much weaker than most similar companies.
Has Compass Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.63 points, from 36.71 to 39.34.
PositoAI is for research and education only and is not investment advice.